newsimpactscreener

Insights

Articles Topics Quotes The Arena Famous Traders CEOs Research

Free services

Daily News Briefing Market Screenings

Pricing Docs Blog Sign in Sign up

newsimpactscreener

Insights

Articles Topics Quotes The Arena Famous Traders CEOs Research

Free services

Daily News Briefing Market Screenings

Pricing Docs Blog Sign in Sign up

newsimpactscreener— news connected to markets.

@newsimpactscrnr on X @newsimpactscreener on Instagram About Briefings Terms Privacy

newsimpactscreener

Insights

Articles Topics Quotes The Arena Famous Traders CEOs Research

Free services

Daily News Briefing Market Screenings

Pricing Docs BlogSign in Sign up

Back to The Tape

GlobeNewsWire

14 Aug 2026, 22:30 UTC · 9w ago

Avicanna Reports Q2 2026 Financial Results

Impact · against what's priced in

Avicanna shows strong operational momentum through proprietary product growth and the imminent Q3 launch of its QUIX™ portfolio. While a reimbursement cut at MyMedi.ca creates a headwind, the overall shift toward high-margin proprietary sales and US rescheduling progress provides a positive catalyst.

AVCN+0.60: No priced-in read yet
In context: The transition of QUIX™ technology to a commercial launch in Q3 with 35+ listings, coupled with 48% QoQ growth in proprietary product sales, shifts the company from R&D toward a scalable commercial model.
Read from the article alone

Avicanna Reports Q2 2026 Financial Results

AVCN

Search tags

Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Create my briefing

What the story claims

4 claims · scored −1 bearish … +1 bullish

What matters in this story

1
Avicanna is launching its proprietary QUIX™ rapid-onset portfolio in Q3 2026 with over 35 commercial listings already secured.
+0.60
More positive than 94% of claims this week
2
U.S. federal authorities have taken initial steps to reschedule certain cannabinoid-based products from Schedule I to Schedule III.
+0.50

Read original · https://www.globenewswire.com/news-release/2026/08/14/3345671/0/en/avicanna-reports-q2-2026-financial-results.html

Actual

Scored by the NIS engine · methodology.

More positive than 88% of claims this week

3

Proprietary product sales grew 48% quarter-over-quarter and 33% year-over-year, contributing to an improved gross margin of 57%.

+0.40

More positive than 81% of claims this week

4

MyMedi.ca experienced its first sequential quarterly revenue decline due to a 30% reduction in Veterans Affairs Canada (VAC) reimbursement rates.

-0.30

More negative than 76% of claims this week

Which stocks this story touches

How each ticker is affected

AVCN+0.80
More positive than 90% of ticker scores this week
The company reported improved gross margins, strong growth in proprietary product sales, and progress toward profitability and new product launches.

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

$AVCN

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

Actual · AVCN

—

No price for AVCN right now — the quote feed didn't answer.

Avicanna Reports Q2 2026 Financial Results — AVCN +0.80 · News Impact Screener